Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00398112
Other study ID # NCI-2012-01830
Secondary ID NCI-2012-01830NC
Status Completed
Phase Phase 2
First received November 9, 2006
Last updated April 28, 2014
Start date August 2007
Est. completion date January 2011

Study information

Verified date December 2012
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Sunitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.


Description:

PRIMARY OBJECTIVES:

I. Assess the response rate (complete response [CR] and partial response) in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma treated with sunitinib malate.

II. Assess the toxicity of this drug in these patients. III. Assess duration of response, time to progression, overall survival, and CR rate in patients treated with this drug.

SECONDARY OBJECTIVES:

I. Evaluate if known risk stratification parameters (i.e., immunoglobulin mutational status, ZAP-70 status, fluorescent in situ hybridization [FISH] defects, and/or CD38 status) are related to clinical response to sunitinib malate.

OUTLINE: This is a multicenter study.

Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Patients undergo blood collection periodically for translational and pharmacological studies, including IgVH gene mutation status and ZAP-70 status. Samples are examined by fluorescent in situ hybridization (FISH) and other assays.

After completion of study treatment, patients are followed every 3 months for up to 2 years.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date January 2011
Est. primary completion date November 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of 1 of the following:

- Biopsy proven small lymphocytic lymphoma (SLL)

- Chronic lymphocytic leukemia (CLL) meeting all of the following criteria:

- Peripheral blood lymphocyte count > 5,000/mm^3

- Lymphocytes must consist of small to moderate size lymphocytes, with < 55% prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically

- Immunophenotyping consistent with CLL, defined by the following criteria:

- Predominant population of lymphocytes share both B-cell antigens (i.e., CD19, CD20, or CD23) as well as CD5 in the absence of other pan-T-cell markers (e.g., CD3 or CD2)

- Dim surface immunoglobulin expression

- Exclusively kappa and lambda light chains

- Splenomegaly, hepatomegaly, or lymphadenopathy are not required

- Refractory or relapsed disease as evidenced by 1 of the following criteria:

- Progression after = 1 course of a purine nucleoside (i.e., fludarabine phosphate, cladribine, pentostatin) regimen

- Progression after = 1 course of an alkylator (i.e., cyclophosphamide or chlorambucil) regimen

- Relapse after = 1 prior purine nucleoside oral kylator (i.e., cyclophosphamide or chlorambucil) regimen

- Requires chemotherapy, as indicated by any of the following criteria:

- Measurable (i.e., > 5,000/mm^3) and progressive clonal lymphocytosis

- Measurable (i.e., single diameter > 2 cm) and progressive lymphadenopathy

- Disease-related symptoms, including 1 or more of the following:

- Weight loss > 10% within the past 6 months

- Extreme fatigue attributed to CLL/SLL

- Fevers > 100.5^oF for 2 weeks without evidence of infection

- Night sweats without evidence of infection

- Evidence of progressive marrow failure, as manifested by the development of or worsening anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelet count < 100,000/mm^3)

- Massive (i.e. > 6 cm below left costal margin) or progressives plenomegaly

- No mantle cell lymphoma, as demonstrated by a negative fluorescent in situ hybridization (FISH) analysis fort(11;14)(IgVH/CCND1) on peripheral blood or tissue biopsy

- ECOG performance status 0-2

- Life expectancy = 12 months

- Creatinine = 1.5 times upper limit of normal (ULN) OR creatinine clearance = 60 mL/min

- AST and ALT = 2.5 times ULN

- Bilirubin normal

- Alkaline phosphatase = 3 times ULN

- Platelet count > 30,000/mm^3 (without transfusion)

- Absolute neutrophil count > 1,000/mm^3

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- Able to complete patient diaries alone or with assistance

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days

- No other malignancy except for squamous cell or basal cell carcinoma of the skin or in situ carcinoma of the cervix, unless the tumor was curatively treated within the past 2 years

- No history of allergic reactions attributed to compounds of similar chemical or biological composition to sunitinib malate

- No inability to swallow or retain sunitinib malate capsules due to any of the following:

- Gastrointestinal tract disease

- Requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No pre-existing thyroid abnormality that would make the patient unable to maintain normal thyroid function with medication

- No pulmonary embolism within the past 12 months

- No serious or nonhealing wound, ulcer, or bone fracture

- No uncontrolled intercurrent illness including, but not limited to, any of the following:

- Ongoing or active infections

- Psychiatric illness or social situation that would limit compliance with study requirements

- No cerebrovascular accident or transient ischemic attack within the past 12 months

- No uncontrolled hypertension (i.e., systolic blood pressure [BP] = 140 mm Hg or diastolic BP = 90 mm Hg)

- No significant cardiac arrhythmia, including any of the following:

- QTc prolongation (i.e., QTc interval = 500 msec)

- Ventricular tachycardia

- Atrial fibrillation

- Atrial flutter

- Second or third degree heart block

- No cardiac disease within the past 12 months, including any of the following:

- Myocardial infarction

- Cardiac arrhythmia

- Stable/unstable angina

- Symptomatic congestive heart failure

- Coronary/peripheral artery bypass graft or stenting

- No New York Heart Association (NYHA) class III or IV heart failure

- The following patients are eligible provided they have NYHA class II cardiac function on baseline ECHO/MUGA:

- History of NYHA class II heart failure and asymptomatic on treatment

- No prior anthracycline exposure

- No prior central thoracic radiation that included the heart in the radiation port

- See Disease Characteristics

- At least 4 weeks since prior chemotherapy

- At least 4 weeks since prior rituximab or alemtuzumab

- At least 4 weeks since prior major surgery

- At least 4 weeks since prior oral steroids

- No prior treatment with any other antiangiogenic agent, including any of the following:

- Bevacizumab

- Sorafenib

- Pazopanib

- AZD2171

- Vatalanib

- VEGF Trap

- At least 7 days since prior and no concurrent CYP3A4 inhibitors, including any of the following:

- Ketoconazole

- Itraconazole

- Clarithromycin

- Erythromycin

- Diltiazem

- Verapamil

- HIV protease inhibitors (i.e., indinavir, saquinavir,ritonavir, atazanavir, nelfinavir)

- Delavirdine

- At least 12 days since prior and no concurrent CYP3A4 inducers, including any of the following:

- Rifampin

- Rifabutin

- Carbamazepine

- Phenobarbital

- Phenytoin

- Hypericum perforatum (St. John's wort)

- Efavirenz

- Tipranavir

- No other concurrent investigational agents

- No concurrent agents with proarrhythmic potential, including any of the following:

- Terfenadine

- Quinidine

- Procainamide

- Disopyramide

- Sotalol

- Probucol

- Bepridil

- Haloperidol

- Risperidone

- Indapamide

- Flecainide

- No concurrent combination antiretroviral therapy for HIV-positive patients

- No other concurrent anticancer agents or therapies

- No concurrent therapeutic doses of coumarin-derivative anticoagulants (e.g., warfarin)

- Concurrent prophylactic low molecular weight heparin or warfarin at doses = 2 mg daily for thrombosis prophylaxis allowed

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • B-cell Chronic Lymphocytic Leukemia
  • Leukemia
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Leukemia, Lymphoid
  • Lymphoma
  • Recurrent Small Lymphocytic Lymphoma
  • Refractory Chronic Lymphocytic Leukemia

Intervention

Drug:
sunitinib malate
Given orally
Other:
pharmacological study
Correlative studies
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States North Central Cancer Treatment Group Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With a Confirmed Response [Complete Response (CR) and Partial Response (PR)] on 2 Consecutive Evaluations at Least 4 Weeks Apart National Cancer Institute working group criteria (NCIWG) was used to assess response.
CR: no lymphadenopathy, hepatomegaly, splenomegaly or constitutional symptoms; normal complete blood count; confirmed by bone marrow (BM) aspirate & biopsy
PR: 50% decrease in peripheral blood lymphocytes, lymphadenopathy, liver/spleen size, presence/absence of constitutional symptoms; plus =1 of the following: =1500/µL polymorphonuclear leukocytes, >100000/µL platelets, >11.0 g/dL hemoglobin or 50% improvement for these parameters without transfusions
Duration of Treatment (up to 12 cycles) No
Secondary Complete Response Rate in Patients With B-cell Chronic Lymphocytic Leukemia Complete response is described in the primary outcome Duration of Treatment (up to 12 cycles) No
Secondary Survival Time Survival time was defined as the time from registration to death due to any cause. The distribution of survival time was estimated using the Kaplan-Meier method. Duration of study (up to 2 years) No
Secondary Progression-free Survival Progression-free survival (PFS) was defined as the time from registration to progression or death due to any cause. The distribution of PFS was estimated using the Kaplan-Meier method. Duration of study (up to 2 years) No
Secondary Duration of Response Duration of response was calculated from the documentation (date) of first response (CR or PR) until the date of progression or last follow-up in the subset of patients who responded. The median duration of response with 95%CI was estimated using the Kaplan Meier method Duration on study (up 2 years) No
See also
  Status Clinical Trial Phase
Completed NCT03045328 - Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Phase 2
Completed NCT01527045 - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Phase 2
Active, not recruiting NCT02153580 - Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Phase 1
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT02254772 - A Phase I/II Study of Intratumoral Injection of SD-101 Phase 1/Phase 2
Active, not recruiting NCT01369849 - Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Phase 1/Phase 2
Completed NCT01427881 - Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Phase 2
Completed NCT01233921 - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer N/A
Completed NCT01093586 - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00006473 - Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Phase 2
Completed NCT00005803 - Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Phase 1/Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Active, not recruiting NCT04230304 - Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Phase 2
Recruiting NCT03246906 - Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Phase 2
Terminated NCT01678443 - Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Phase 1
Active, not recruiting NCT01815749 - Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04007029 - Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT04892277 - CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1